Author: Daniel B Larremore; Bailey K Fosdick; Kate M Bubar; Sam Zhang; Stephen M Kissler; C. Jessica E. Metcalf; Caroline Buckee; Yonatan Grad
Title: Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys Document date: 2020_4_20
ID: c4cs14ja_3
Snippet: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mil.....
Document: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mild and asymptomatic infections (1) . In this context, serological surveillance has the potential to provide information about the true number of infections, allowing for robust estimates of case and infection fatality rates and for the parameterization of epidemiological models to evaluate the possible impacts of specific interventions and thus guide public health decision-making.
Search related documents:
Co phrase search for related documents- future epidemic and population seropositivity: 1
- future epidemic and possible impact: 1, 2, 3, 4
- future epidemic and public health: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68
- future epidemic and public health decision making: 1
- gap address and infection fatality: 1, 2
- gap address and possible impact: 1
- public health and response critical component: 1, 2, 3, 4, 5, 6
- public health and robust estimate: 1, 2, 3, 4, 5
- public health and serological surveillance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- public health and serological testing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- public health and specific intervention: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- public health and true number: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- public health and viral diagnostic testing: 1, 2, 3, 4
- public health decision making and serological testing: 1, 2
- public health decision making guide and serological testing: 1
- robust estimate and serological surveillance: 1, 2
- robust estimate and serological testing: 1, 2
- serological surveillance and true number: 1
- serological testing and viral diagnostic testing: 1, 2
Co phrase search for related documents, hyperlinks ordered by date